ArticleCancers2021

The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Jean-Noël Hubert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.